Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated influenza vaccine 2016-2017
- Development stage
- Unknown
- Lead developer
- University Health Network
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 2016-2017 flu vaccine refers to the seasonal trivalent inactivated influenza vaccine (TIV) formulations used during the 2016-2017 Northern Hemisphere influenza season. These vaccines contain inactivated antigens from three influenza strains: A/California/7/2009 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus. In clinical research, such as the trial conducted by the University Health Network (NCT03139565), these vaccines were used to compare the immunogenicity of high-dose formulations (e.g., Sanofi Pasteur's Fluzone High-Dose) against standard-dose formulations (e.g., GSK's Fluviral) in specific populations like solid organ transplant recipients. The vaccine works by stimulating the immune system to produce hemagglutination inhibition antibodies and cellular immune responses against the viral hemagglutinin protein, thereby preventing seasonal influenza infection.
- Brand names
- Fluzone High-DoseFluviral
- Other names
- 2016-2017 seasonal influenza vaccineTIV 2016-2017TIV2016-2017TIV-2016-2017flu vaccine 2016-2017
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on trivalent inactivated influenza vaccine 2016-2017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated influenza vaccine 2016-2017.